Supplement: ESCRS Clinical Trends Series: Retina

In this edition of the ESCRS Clinical Trends Series, ESCRS President Prof. Burkhard Dick draws on findings from the 2025 ESCRS Clinical Trends Survey to present an anterior as well as posterior segment surgeon’s perspective on current and emerging trends in retina care.

Cataract Surgery in Diabetic Patients

Information on retinopathy-related risks provides foundation for decisions on procedure timing and follow-up.

Nearly all adults with diabetes who live long enough will develop vision-impairing cataracts, but decisions on surgical timing must consider the procedure’s benefits and risks in this patient population...

Author: Cheryl Guttman Krader

First-Line Therapy for Non-Infectious Uveitis

Experts offer differing perspectives on the relative benefits and drawbacks of biologics versus traditional IMT.

Uveitis experts agree that biologics are effective in treating non-infectious uveitis (NIU), but opinions differ regarding their use as a first-line therapy. In a point-counterpoint discussion...

Author: Cheryl Guttman Krader

GLP-1RAs: A Cause for Concern?

Risk and benefits of revolutionary semaglutide and tirzepatide treatments from an ophthalmological point of view.

Ophthalmologists have recently raised concerns regarding the effect of GLP-1RAs on the retina that, despite their many beneficial effects, need serious consideration...

Author: Timothy Norris

Retinal Detachment After Cataract Surgery

Knowledge of risk factors directs patient management and informed consent.

The incidence of rhegmatogenous retinal detachment (RRD) is increasing globally, and cataract/refractive lens surgery is a known risk factor for this event...

Author: Cheryl Guttman Krader

MCO-010 Optogenetic Therapy for Vision Restoration

Long-term study documents durable safety and efficacy profiles in advanced retinitis pigmentosa.

A single intravitreal injection of MCO-010 optogenetic therapy continues to demonstrate safety and is providing durable, clinically meaningful vision improvement in patients suffering severe and permanent vision loss...

Author: Cheryl Guttman Krader

Targeting the Intravitreal Treatment Burden

Novel systemic nanomedicine agent shows promising safety and efficacy in patients with bilateral retinal disease.

Positive end-of-study outcomes in a phase 2 clinical trial appear to strongly support further development of subcutaneous migaldendranib (subQ MGB) for the treatment of diabetic macular oedema (DME)...

Author: Cheryl Guttman Krader

Treatment for Macular Oedema Secondary to Inflammation

Bispecific biologic shows early promise.

Preliminary results from a phase 1b clinical trial show that intravitreal treatment with KSI-101 was associated with robust anatomic and visual improvement...

Author: Cheryl Guttman Krader

Privosegtor Shows Promise for AON

Improved low contrast visual acuity and reduced retinal ganglion cell loss seen in patients with acute optic neuritis.

An investigative neuroprotective agent, privosegtor (OCS-05), appears to be promising as an add-on to standard of care treatment for acute optic neuritis (AON), a recent clinical study suggests...

Author: Cheryl Guttman Krader

AI and Gene Therapy as the Next Frontier

Effective new treatments are entering the clinic for uveitis.

The use of artificial intelligence (AI) and taking a ‘cross-sciences’ research approach holds the key to unlocking better future treatment pathways for uveitis...

Author: Priscilla Lynch